Rift Valley Fever

Development of the ChAdOx1 RVF vaccine


Research Description:

This vaccine programme exploit synergies in human and livestock immunology to accelerate development of candidate vaccines for deployment in humans and the respective animal hosts of infection. Using this approach, we have developed ChAdOx1 RVF, a novel chimpanzee adenovirus vectored Rift Valley Fever vaccine, that is highly efficacious in multiple target livestock species (sheep, goats, cattle) and is currently in human phase I clinical trials (NCT04754776, NCT04672824). We have worked on a similar One Health vaccine for use against Middle East Respiratory Syndrome (MERS) in camels and humans, and our veterinary research programmes continue to inform advances in human vaccinology.